Skip to content. | Skip to navigation

National Cancer Institute U.S. National Institutes of Health www.cancer.gov

Navigation

Personal tools

You are here: Home / Biomarkers / MPPED2

MPPED2

Basics

Aliases:
This biomarker is also known as:
  • dJ873F21.1,
  • FAM1B,
  • Fetal brain protein 239,
  • metallophosphoesterase MPPED2,
  • chromosome 11 open reading frame 8,
  • C11orf8,
  • Q15777,
  • D11S302E,
  • metallophosphoesterase domain-containing protein 2,
  • 239FB,
  • dJ1024C24.1,
  • EC 3.1.-.-,
  • c11orf8,
  • metallophosphoesterase domain containing 2,
  • Hs.46638,
  • fetal brain protein 239,
  • Metallophosphoesterase domain-containing protein 2,

View in BioMuta

Description…

MPPED2 displays low metallophosphoesterase activity (in vitro) and may play a role in the development of the brain and nervous system (by similarity). Alternatively spliced transcript variants have been described.

Attributes

QA State: Curated
Type: Protein
Short Name:
HGNC Name: MPPED2

Datasets

There are no datasets associated with this biomarker.

Organs

The following organs have data associated with this biomarker…

Ovary

Attributes

Phase: Two
QA State: Under Review

Overview

Mpped2 expression has been shown to impair neuroblastoma tumorigenesis in mice.

Performance Comment

MPPED2 (C11ORF8) was one of 50 tumor vasculature-associated genes with transmembrane or secreted protein products identified through expression profiling of ovarian cancer vascular cells. These 50 tumor vascular markers (TVMs) also had low or no expression in normal tissues. MPPED2 (C11ORF8) was not in the group of 13 selected for further validation.

Prostate

Attributes

Phase: One
QA State: Under Review

Overview

Performance Comment

Studies

This biomarker is currently being annotated or is under review. You must be logged in or do not have permission to view any additional information. Contact Heather Kincaid at heather.kincaid@jpl.nasa.gov if you should have access to this biomarker.

2015 EDRN PI Orientation

The New and Continuing EDRN Principal Investigator Orientation will take place October 15–16, 2015 in Bethesda, Maryland.

Announcement 06/30/2015

A funding opportunity for a new pancreatic cancer initiative, called The Pancreatic Cancer Detection Consortium (U01), has been released. For more information, please go to http://grants.nih.gov /grants/guide/ pa-files/ PAR-15-289.html.

Announcement 04/08/2015

Thank you to everyone who made the 29th EDRN Steering Committee Meeting a success. The orientation for new and continuing EDRN PIs will be held October 15-16, 2015 on the NCI campus. More information will be available later this summer.